Listing of Claims

1. **(currently amended)** A compound ~~**of formula I,**~~ **a stereochemical isomer of the compound, or a hydrate, solvate, or pharmaceutically acceptable salt of the compound or isomer, wherein**:

the compound corresponds in structure to formula I:



;

~~**one of their stereochemically isomer forms or a pharmaceutically acceptable salt thereof, wherein:**~~

R_4 is selected from the group consisting of N and S;

if R_4 is S, then R_1 is H, and R_2 is absent;

if R_4 is N, then R_1 and R_2 are H or are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; ~~**if R_4=S then R_1 is H and R_2 is absent;R_4 is selected from the group consisting of N and S;**~~

n ~~**being an integrer from 0 to**~~ **is zero or** 1;

X is selected from the group consisting of C_2-C_{10}-alkyl**ene**, C_2-C_{10}-alkenyl**yne,** and -CH_2-Y-CH_2-; ~~**wherein**~~

Y is phenyl;

m ~~**being an integrer from**~~ **is** 1 **[[to]] or** 2;

R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl**,** and **phenoxy** ~~**-O-phenyl**~~, wherein**:**

the **quinolyl, the** aromatic ring of the chromanyl ~~**moiety, the quinolyl, and**~~ **[[or]]** the phenyl **ring of the phenoxy are** ~~**residue is**~~ optionally substituted **[[by]] with** one or more ~~**groups chosen**~~ **substituents independently selected** from **the group consisting of** C_1-C_6-alkoxy, C_1-C_6-alkyl, halogen, C_2-C_6-alkenyl, halo-(C_1-C_6)-alkyl, halo-(C_1-C_6)-

alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1-C_6-alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1-C_6-alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1-C_6-alkyl-carbonylamino, hydroxy, cyano, nitro, amino, N-(C_1-C_6)-alkylamino, N,N-(C_1-C_6)-dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6)alkylaminosulfonyl, **and** **[[or]]** (C_1-C_6)alkylsulfonylamino, **wherein:**

the C_1-C_6-alkyl portion of any of the alkyl-comprising substituents is optionally substituted with a substituent independently selected from the group consisting of hydroxy and amino; or ~~wherein~~

the phenyl ring **of the phenoxy** is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl; ~~wherein each alkyl is optionally substituted with hydroxy or amino;~~

provided that the compound is not

2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole,

3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine,

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine,

3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine,

2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, **[[or]]**

3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine, **or** ~~and is not~~

3-[3-[(chroman-2-yl)methylamino]**propyl**]-2,4-**dioxoimidazolidine** ~~dioxoimidazoidine~~.

2. **(currently amended)** ~~Compound~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 1, wherein R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl, and **phenoxy** ~~-O-phenyl~~, wherein:

the phenyl **ring of the phenoxy** ~~residue~~ is optionally substituted ~~by a group chosen~~ **with a substituent selected** from **the group consisting of** C_1-C_6-alkoxy, C_1-C_6-alkyl, **[[or]]** **and** halogen. **[[;]]**

3. **(currently amended)** ~~Compound~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 1 **[[or 2]]**, wherein:

m is 1; and

R_3 is chroman-2-yl.

4. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 3, wherein:

R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; and

R_4 is N.

5. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**any of claims**~~ **claim** 3 **[[to 4]]**, wherein X is selected from the group consisting of C_2-C_{10}-alkyl**ene**, (*E*)-2-butenyl**ene**, ~~**3-methylbenzyl or 4-methylbenzyl.**~~



, and

6. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 3, wherein:

R_1 is H; **[[,]]**

R_2 is absent; and

R_4 is S.

7. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 6, wherein:

n is **zero; [[0]]** and

X is C_2-C_{10}-alkyl**ene**.

8. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 1 **[[or 2]]**, wherein:

m **is [[=]]** 2; and

R_3 is **phenoxy** ~~**-O-phenyl**~~, wherein the phenyl **ring of the phenoxy:** ~~**residue**~~ is optionally substituted **[[by]] with** one or more ~~**groups chosen**~~ **substituents**

independently selected from **the group consisting of** C_1-C_6-alkoxy, C_1-C_6-alkyl, halogen, C_2-C_6-alkenyl, halo-(C_1-C_6)-alkyl, halo-(C_1-C_6)-alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1-C_6-alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1-C_6-alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1-C_6-alkylcarbonylamino, hydroxy, cyano, nitro, amino, N-(C_1-C_6)-alkylamino, N,N-(C_1-C_6)-dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6)alkylaminosulfonyl**, and [[or]]** (C_1-C_6)alkylsulfonylamino; or ~~**wherein the phenyl ring**~~

is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl.

9. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 8, wherein:

R_3 is phenoxy, wherein the phenyl **[[group]] ring of the phenoxy:**

is optionally substituted **[[by]] with** one or more ~~**groups chosen**~~ **substituents independently selected** from **the group consisting of** phenyl, C_1-C_6-alkoxycarbonyl, C_1-C_6-alkylcarbonylamino, C_1-C_6-alkoxy, C_1-C_6-alkyl, halo-(C_1-C_6)-alkyl, **and [[or]]** halogen, or ~~**wherein the phenyl group**~~

is substituted by two **neighbouring** ~~**neigbouring**~~ residues, which together with the phenyl group to which they are attached form tetrahydronaphthyl.

10. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 9, wherein the phenyl ~~**residue**~~ **ring of the phenoxy** is optionally substituted **[[by]] with** one or more ~~**groups chosen**~~ **substituents independently selected** from **the group consisting of** methoxy, ethoxy, propoxy, isopropoxy, ethyl, propyl, isopropyl, bromide, trifluoromethyl, ~~**methylamide**~~ **methylamido, and [[or]]** ethoxycarbonyl.

11. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**any of claims**~~ **claim** 8 **[[to 10]]**, wherein **R_3 is phenoxy, wherein:**

the phenyl ~~**group**~~ **ring of the phenoxy** is substituted in ortho- and/or meta- position.

12. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**any of claims**~~ **claim** 8 **[[to 11]]**, wherein**:**

R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; and

R_4 is N.

13. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**any of claims**~~ **claim** 8 **[[to 12]]**, wherein**:**

n is **[[0]] zero**; and

X is C_2-C_{10}-alkyl**ene**.

14. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**any of claims**~~ **claim** 8 **[[to 11]]**, wherein**:**

R_1 is H**; [[and]]**

R_2 is absent**;** and

R_4 is S.

15. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 14, wherein**:**

n is **[[0]] zero**; and

X is C_2-C_{10}-alkyl**ene**.

16. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**claims**~~ **claim** 1 **[[or 2]]**, wherein**:**

m is 1**;** and

R_3 is 2-quinolyl.

17. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 16, wherein:

R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring**; and**

R_4 is N.

18. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to ~~**any of claims**~~ claim 16 **[[to 17]]**, wherein:

n is **zero [[0]]**; and

X is C_2-C_{10}-alkyl**ene**.

19. **(currently amended)** ~~**Compound**~~ **The compound, isomer, hydrate, solvate, or salt** according to claim 1, wherein the compound is selected from **the group consisting of**:

~~**(a) 2-[4-[(Chroman-2(*R*)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;**~~

[[(b)]]

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

[[(c)]]

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*a*]pyrazine;

[[(d)]]

2-[5-[(Chroman-2-yl)methylamino]pentyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(e)]]

2-[6-[(Chroman-2-yl)methylamino]hexyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(f)]]

2-[3-[(Chroman-2-yl)methylamino]propyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(g)]]

3-[8-[(Chroman-2-yl)methylamino]octyl]-2,4-dioxothiazolidine;

~~**(h) 2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;**~~

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(i)]]

2-[8-[(Chroman-2-yl)methylamino]octyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(j)]]

2-[3-[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(k)]]

2-[4-[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

~~**(l) (*E*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;**~~

2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(m)]]

2-[4-[2-(*o*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(n)]]

2-[4-[2-(*m*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(o)]]

2-[4-[2-(*o*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(p)]]

2-[4-[2-(*m*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(q)]]

2-[4-[2-(*o*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(r)]]

2-[4-[2-(*m*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(s)]]

2-[4-[2-(*o*-Isopropylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(t)]]

2-[4-[(2-quinolyl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(u)]]

2-[4-[2-(o-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

[[(v)]]

2-[4-[2-(o-Isopropoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]

imidazole;

[[(w)]]

2-[4-[2-[m-(Trifluoromethyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo [1,2-*c*] imidazole;

[[(x)]]

2-[4-[2-(1,1'-Biphenyl-2-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(y)]]

2-[4-[2-[*o*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(z)]]

2-[4-[2-[*m*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(aa)]]

2-[4-[2-[*o*-(Ethoxycarbonyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(bb)]]

2-[4-[2-(5,6,7,8-Tetrahydronaphth-1-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo [1,2-*c*]imidazole;

[[(cc)]]

2-[4-[2-(2,3-Dimethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(dd)]]

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,4-dioxoperhydropyrido[1,2-*a*]pyrazine;

~~**(ee) (*Z*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole;**~~

2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole;

[[(ff)]]

3-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-2,4-dioxothiazolidine;

[[(gg)]]

3-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-2,4-dioxothiazolidine;

[[(hh)]]

3-[8-[2-(*o*-Ethoxyphenoxy)ethylamino]octyl]-2,4-dioxothiazolidine;

[[(ii)]]

2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

[[(jj)]]

2-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

[[(kk)]]

2-[4-[(2-Quinolyl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine; **and**

[[(ll)]]

2-[6-[(2-Quinolyl)methylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

~~**a pharmaceutically acceptable salt or one of their stereochemically isomer forms**~~.

20. **(currently amended)** ~~**Pharmaceutical**~~ **A pharmaceutical** composition which comprises:

a therapeutically effective amount of a compound**, a stereochemical isomer of the compound, or a hydrate, solvate, or pharmaceutically acceptable salt of the compound or isomer, wherein the compound is selected from the group of compounds recited in claim 1;** ~~**as claimed in any of claims 1 to 19**~~ and [[,]]

one or more pharmaceutically acceptable carriers.

21. **(currently amended)** [[Use]] **A use** of a compound**, a stereochemical isomer of the compound, or a hydrate, solvate, or pharmaceutically acceptable salt of the compound or isomer** ~~**of formula I according to any of claims 1 to 19, wherein the disclaimer to 3-[3-[(chroman-2-yl)methylamino]propyl]-2,4-dioxoimidazolidine does not apply,**~~ for the preparation of a medicament for the treatment and/or prophylaxis of a **condition selected from the group consisting of** Parkinson Disease, cerebral damage by thromboembolitic ictus, craneoencephalic traumatisms, depression, migraine, pain, psychosis, anxiety disorders,

aggressive disorders, and [[or]] urinary tract disorders, wherein:

the compound corresponds in structure to formula I:



;

R_4 is selected from the group consisting of N and S;

if R_4 is S, then R_1 is H, and R_2 is absent;

if R_4 is N, then R_1 and R_2 are H or are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring;

n is zero or 1;

X is selected from the group consisting of C_2-C_{10}-alkylene, C_2-C_{10}-alkenylyne, and -CH_2-Y-CH_2-;

Y is phenyl;

m is 1 or 2;

R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl, and phenoxy, wherein:

the quinolyl, the aromatic ring of the chromanyl, and the phenyl ring of the phenoxy are optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_6-alkoxy, C_1-C_6-alkyl, halogen, C_2-C_6-alkenyl, halo-(C_1-C_6)-alkyl, halo-(C_1-C_6)-alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1-C_6-alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1-C_6-alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1-C_6-alkyl-carbonylamino, hydroxy, cyano, nitro, amino, N-(C_1-C_6)-alkylamino, N,N-(C_1-C_6)-dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6)alkylaminosulfonyl, and (C_1-C_6)alkylsulfonylamino, wherein:

the C_1-C_6-alkyl portion of any of the alkyl-comprising

substituents is optionally substituted with a substituent independently selected from the group consisting of hydroxy and amino; or

the phenyl ring of the phenoxy is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl;

provided that the compound is not

2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole,

3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine,

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine,

3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine,

2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, or

3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

22. **(new)** The use according to claim 21, wherein the compound is selected from the group consisting of:

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*a*]pyrazine;

2-[5-[(Chroman-2-yl)methylamino]pentyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[6-[(Chroman-2-yl)methylamino]hexyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[3-[(Chroman-2-yl)methylamino]propyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

3-[8-[(Chroman-2-yl)methylamino]octyl]-2,4-dioxothiazolidine;

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[8-[(Chroman-2-yl)methylamino]octyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[3-[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(*o*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(*m*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(*o*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*m*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*o*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*m*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*o*-Isopropylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[(2-quinolyl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(o-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(o-Isopropoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[m-(Trifluoromethyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo [1,2-*c*]imidazole;

2-[4-[2-(1,1'-Biphenyl-2-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[*o*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[*m*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[*o*-(Ethoxycarbonyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(5,6,7,8-Tetrahydronaphth-1-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo [1,2-*c*]imidazole;

2-[4-[2-(2,3-Dimethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,4-dioxoperhydropyrido[1,2-*a*]pyrazine;

2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole;

3-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-2,4-dioxothiazolidine;

3-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-2,4-dioxothiazolidine;

3-[8-[2-(*o*-Ethoxyphenoxy)ethylamino]octyl]-2,4-dioxothiazolidine;

2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

2-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

2-[4-[(2-Quinolyl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine; and

2-[6-[(2-Quinolyl)methylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine.

23. **(new)** The use according to claim 21, wherein the isomer of the compound is selected from the group consisting of:

2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

(*E*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole; and

(*Z*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole.

24. **(new)** A method for preventing and/or treating a condition selected from the group consisting of cerebral damage caused by thromboembolitic stroke or traumatic brain damage, Parkinson's disease, depression, migraine, pain, psychosis, mood disorder, and urinary tract disorder in a subject in need of such prevention and/or treatment, wherein:

the method comprises administering to the subject a compound, a stereochemical isomer of the compound, or a hydrate, solvate, or pharmaceutically acceptable salt of the compound or isomer, wherein:

the compound corresponds in structure to formula I:



;

R_4 is selected from the group consisting of N and S;

if R_4 is S, then R_1 is H, and R_2 is absent;

if R_4 is N, then R_1 and R_2 are H or are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring;

n is zero or 1;

X is selected from the group consisting of C_2-C_{10}-alkylene, C_2-C_{10}-alkenylyne, and -CH_2-Y-CH_2-;

Y is phenyl;

m is 1 or 2;

R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl, and phenoxy, wherein:

the quinolyl, the aromatic ring of the chromanyl, and the phenyl ring of the phenoxy are optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_6-alkoxy, C_1-C_6-alkyl, halogen, C_2-C_6-alkenyl, halo-(C_1-C_6)-alkyl, halo-(C_1-C_6)-alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1-C_6-alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1-C_6-alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1-C_6-alkyl-carbonylamino, hydroxy, cyano, nitro, amino, N-(C_1-C_6)-alkylamino, N,N-(C_1-C_6)-dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6)alkylaminosulfonyl, and (C_1-C_6)alkylsulfonylamino, wherein:

the C_1-C_6-alkyl portion of any of the alkyl-comprising substituents is optionally substituted with a substituent independently selected from the group consisting of hydroxy and amino; or

the phenyl ring of the phenoxy is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl;

provided that the compound is not

2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole,

3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine,

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine,

3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine,

2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, or

3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

25. **(new)** The method according to claim 24, wherein the subject is human.

26. **(new)** The method according to claim 24, wherein the condition comprises migraine.

27. **(new)** The method according to claim 24, wherein the condition comprises pain.

28. **(new)** The method according to claim 24, wherein the condition comprises cerebral damage caused by thromboembolitic stroke or traumatic brain damage.

29. **(new)** The method according to claim 24, wherein the condition comprises Parkinson's disease.

30. **(new)** The method according to claim 24, wherein the condition comprises depression.

31. **(new)** The method according to claim 24, wherein the condition comprises psychosis.

32. **(new)** The method according to claim 31, wherein the psychosis comprises schizophrenia.

33. **(new)** The method according to claim 24, wherein the condition comprises a mood disorder.

34. **(new)** The method according to claim 33, wherein the mood disorder comprises an anxiety disorder.

35. **(new)** The method according to claim 33, wherein the mood disorder comprises an aggressive disorder.

36. **(new)** The method according to claim 24, wherein the condition comprises a urinary tract disorder.

37. **(new)** The method according to claim 36, wherein the urinary tract disorder comprises urinary incontinence.

38. **(new)** The method according to claim 24, wherein an effective amount of the compound, isomer, hydrate, solvate, or salt is administered to the subject.

39. **(new)** The method according to claim 24, wherein the compound is selected from the group consisting of:

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*a*]pyrazine;

2-[5-[(Chroman-2-yl)methylamino]pentyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[6-[(Chroman-2-yl)methylamino]hexyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[3-[(Chroman-2-yl)methylamino]propyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

3-[8-[(Chroman-2-yl)methylamino]octyl]-2,4-dioxothiazolidine;

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[8-[(Chroman-2-yl)methylamino]octyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[3-[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(*o*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(*m*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]

imidazole;

2-[4-[2-(*o*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*m*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*o*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*m*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(*o*-Isopropylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[(2-quinolyl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(o-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

2-[4-[2-(o-Isopropoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[m-(Trifluoromethyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo [1,2-*c*]imidazole;

2-[4-[2-(1,1'-Biphenyl-2-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[*o*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[*m*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-[*o*-(Ethoxycarbonyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[2-(5,6,7,8-Tetrahydronaphth-1-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo [1,2-*c*]imidazole;

2-[4-[2-(2,3-Dimethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole;

2-[4-[(Chroman-2-yl)methylamino]butyl]-1,4-dioxoperhydropyrido[1,2-*a*]pyrazine;

2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole;

3-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-2,4-dioxothiazolidine;

3-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-2,4-dioxothiazolidine;

3-[8-[2-(*o*-Ethoxyphenoxy)ethylamino]octyl]-2,4-dioxothiazolidine;

2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

2-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

2-[4-[(2-Quinolyl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine; and

2-[6-[(2-Quinolyl)methylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine.

40. **(new)** The method according to claim 24, wherein the isomer of the compound is selected from the group consisting of:

2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

(*E*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole; and

(*Z*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole.

41. **(new)** The compound, isomer, hydrate, solvate, or salt according to claim 1, wherein the isomer of the compound is selected from the group consisting of:

2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

(*E*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-*c*] imidazole; and

(*Z*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*] imidazole.